Angels Ginès
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Angels Ginès has a total of 246 co-authors. Here are the top co-authors by number of shared publications:
- Gloria Fernández-Esparrach
Endoscopy Unit, Gastroenterology Department, ICMDM, Hospital Clinic, UB, C/Villarroel 170, 08036 Barcelona, Spain
17 shared publications Josep Llach
Unidad de Endoscopia, Servicio de Gastroenterología, ICMDiM, Hospital Clínic, CIBERehd, IDIBAPS, Universitat de Barcelona, Barcelona, España
11 shared publications- Antoni Castells
Gastroenterology, Hospital Clínic of Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain
10 shared publications - Maria Pellisé
Gastroenterology Department, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain
7 shared publications - Oriol Sendino
University of Barcelona
7 shared publications - Joan Maurel
Department of Medical Oncology, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Barcelona, Spain
6 shared publications
Latest Publications
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S43-S44
Comparison Of An Artificial Intelligence Capsule Endoscopy System (Navicam) with the conventional Capsule Endoscopy (Pillcam Sb3) In The Study Of Small Bowel Pathology: Navipill Pilot Study
Aims Artificial intelligence can improve reading times and lesion detection rates in Small Bowel Capsule Endoscopy (SBCE).Compare the reading with artificial intelligence (AIR) of the Navicam Capsule with the conventional reading (CR) of PillcamR SB3 (gold standard). Methods Prospective clinical trial comparing AIR and CR (non-inferiority study). The 2 SBCE were administered to the same patient in randomized order with 60-minute intervals. AIR and CR were performed by two independent expert investigators. Diagnostic performance (percentage of lesions compatible with the indication for the test), diagnostic accuracy and reading times of the AIR compared to CR were evaluated. Results Twenty patients (median age 60 ± 10 years) were included. SBCE studies were complete with Navicam and Pillcam in 100% and 95% (p=1). The diagnostic yield by AIR and CR was 80% and 90% (p=0.5). The two readings agreed in 90% of the cases (Cohen's k 0.62). In the analysis per patient, the AIR presented sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy of 88%, 100%, 100%, 60%, and 90%, respectively. In the analysis per lesion, the AIR showed sensitivity, specificity, PPV, NPV, and diagnostic accuracy of 97%, 50%, 95%, 60%, and 93%, respectively. Mean reading time was 3.2 ±3.9 minutes with AIR and 27.5 ±9. 4 minutes with CR (p < 0.001). Conclusions AIR with NavicamR shows high agreement with CR with PillcamR. AI demonstrates high diagnostic yield and accuracy, with a significant reduction of reading times. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S43-S44
Comparison Of An Artificial Intelligence Capsule Endoscopy System (Navicam) with the conventional Capsule Endoscopy (Pillcam Sb3) In The Study Of Small Bowel Pathology: Navipill Pilot Study
Aims Artificial intelligence can improve reading times and lesion detection rates in Small Bowel Capsule Endoscopy (SBCE).Compare the reading with artificial intelligence (AIR) of the Navicam Capsule with the conventional reading (CR) of PillcamR SB3 (gold standard). Methods Prospective clinical trial comparing AIR and CR (non-inferiority study). The 2 SBCE were administered to the same patient in randomized order with 60-minute intervals. AIR and CR were performed by two independent expert investigators. Diagnostic performance (percentage of lesions compatible with the indication for the test), diagnostic accuracy and reading times of the AIR compared to CR were evaluated. Results Twenty patients (median age 60 ± 10 years) were included. SBCE studies were complete with Navicam and Pillcam in 100% and 95% (p=1). The diagnostic yield by AIR and CR was 80% and 90% (p=0.5). The two readings agreed in 90% of the cases (Cohen's k 0.62). In the analysis per patient, the AIR presented sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy of 88%, 100%, 100%, 60%, and 90%, respectively. In the analysis per lesion, the AIR showed sensitivity, specificity, PPV, NPV, and diagnostic accuracy of 97%, 50%, 95%, 60%, and 93%, respectively. Mean reading time was 3.2 ±3.9 minutes with AIR and 27.5 ±9. 4 minutes with CR (p < 0.001). Conclusions AIR with NavicamR shows high agreement with CR with PillcamR. AI demonstrates high diagnostic yield and accuracy, with a significant reduction of reading times. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S254
Prospective and comparative observational study between Single-Balloon Enteroscopy and Motorized Spiral Enteroscopy
Aims Motorized Spiral Enteroscopy (MSE) emerged as a technique with higher insertion depth and shorter exploration time. However, comparative studies with previous techniques are scarce. We aimed to compare Single-Balloon Enteroscopy (SBE) and MSE efficacy and safety. Methods Prospective and comparative observational study conducted on patients undergoing SBE or MSE in a tertiary hospital from December 2019 to July 2022. Demographic characteristics, procedure indication, small bowel exploration time (SBET), technical success, depth of maximum insertion (DMI), diagnostic, therapeutic, interventional yield and adverse events (AE), were collected. Data was analyzed using IBM SPSS Statistics 28.0 [1] [2] [3] [4] [5]. Results A total of 323 enteroscopies (152 SBE and 171 MSE) were performed in 267 patients. Suspected small bowel bleeding was the most frequent indication (72.2%). Insertion was anterograde in 213 cases (123 SBE/ 90 MSE) and retrograde in 110 cases (29 SBE/ 81 MSE). Technical success was 98% with SBE and 92.35% with EMS (p=0.019), performing complete enteroscopies only with MSE (0% vs 10.4%, p<0.001). For the anterograde route, SBE showed significantly lower DMI than MSE (229.80+/-86.32cm vs 430.55+/-211.98cm, p<0.001). No statistical differences were found regarding SBET (39min vs 34.22min, pNS). The diagnostic yield was 72.3% and 65% (pNS), the therapeutic yield was 63.8% and 40.9% (p<0.001), and interventional yield was 86.8% and 68.4% for SBE and MSE, respectively (p<0.001). No differences were found regarding AE rate (4.6% vs 9.3%, pNS). Conclusions Both techniques, SBE and MSE, are effective and safe. SBE has better performance in the therapeutic and interventional yield. MSE allows a higher DMI for the anterograde route. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S254
Prospective and comparative observational study between Single-Balloon Enteroscopy and Motorized Spiral Enteroscopy
Aims Motorized Spiral Enteroscopy (MSE) emerged as a technique with higher insertion depth and shorter exploration time. However, comparative studies with previous techniques are scarce. We aimed to compare Single-Balloon Enteroscopy (SBE) and MSE efficacy and safety. Methods Prospective and comparative observational study conducted on patients undergoing SBE or MSE in a tertiary hospital from December 2019 to July 2022. Demographic characteristics, procedure indication, small bowel exploration time (SBET), technical success, depth of maximum insertion (DMI), diagnostic, therapeutic, interventional yield and adverse events (AE), were collected. Data was analyzed using IBM SPSS Statistics 28.0 [1] [2] [3] [4] [5]. Results A total of 323 enteroscopies (152 SBE and 171 MSE) were performed in 267 patients. Suspected small bowel bleeding was the most frequent indication (72.2%). Insertion was anterograde in 213 cases (123 SBE/ 90 MSE) and retrograde in 110 cases (29 SBE/ 81 MSE). Technical success was 98% with SBE and 92.35% with EMS (p=0.019), performing complete enteroscopies only with MSE (0% vs 10.4%, p<0.001). For the anterograde route, SBE showed significantly lower DMI than MSE (229.80+/-86.32cm vs 430.55+/-211.98cm, p<0.001). No statistical differences were found regarding SBET (39min vs 34.22min, pNS). The diagnostic yield was 72.3% and 65% (pNS), the therapeutic yield was 63.8% and 40.9% (p<0.001), and interventional yield was 86.8% and 68.4% for SBE and MSE, respectively (p<0.001). No differences were found regarding AE rate (4.6% vs 9.3%, pNS). Conclusions Both techniques, SBE and MSE, are effective and safe. SBE has better performance in the therapeutic and interventional yield. MSE allows a higher DMI for the anterograde route. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 27 May 2020
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 52 (06) , 427-428
Novel design fine-needle biopsy needles are ready to take over the supremacy of fine-needle aspiration needles for sampling of solid pancreatic masses
Endoscopic ultrasound (EUS)-guided tissue acquisition is a well-established method for pathological diagnosis of solid tumors wherever the needle can reach. However, there is currently conflicting evidence on whether any specific needle or technique is superior to others. The use of EUS-guided fine-needle biopsy (FNB) needles has generated great interest, based on theoretical advantages over EUS fine-needle aspiration (FNA) needles in improving diagnostic accuracy (if we assume that a bigger sample is better, which is not always true), procurement of samples with preserved tissue (as cytology does not inform on the architecture of the lesion), and allowing immunohistochemistry or special stains required for certain diagnoses. “...the results of this study support the use of EUS-FNB with a fork-tip needle over EUS-FNA in solid pancreatic masses.” Attempts to obtain core tissue samples by EUS require cutting mechanisms. The first device was a trucut needle that had a high number of technical failures and was soon taken off the market. The reverse bevel needle was the first core biopsy needle widely used but, after initial promising results, it did not show unequivocal superiority over FNA. Over the past few years, new core biopsy needles have been manufactured with the aim of assessing an adequate tissue sample while avoiding the technical difficulties that usually appear when sampling the head of the pancreas from the duodenum. One such needle is the fork-tip, opposing bevel design, equipped with six cutting surfaces in an asymmetrical design. This is the EUS-FNB needle used in the study performed by Oppong et al. published in the current issue of Endoscopy [1]. The other is the Franseen design needle that has a three-plane symmetrical cutting surface. Both needles have been designed to maximize tissue capture and minimize fragmentation in order to acquire architecturally intact tissue. Many articles with various methodological designs attempting to assess the performance of different needles in solid pancreatic masses have been published in recent years. Technical tips for tissue acquisition and the impact of on-site evaluation of the sample have been repeatedly tested as well. Moreover, several randomized controlled trials (RCTs) have compared EUS-FNA and EUS-FNB in this setting but reached inconsistent results. Five meta-analyses on the subject were also published within the past 4 years. Among the meta-analyses published to date, most of them [2–4] did not find significant differences between the two methods of tissue sampling in terms of diagnostic accuracy, which is in concordance with the most recent update of European guidelines that recommend FNA and FNB equally for routine sampling of solid masses [5]. However, in most of the mentioned meta-analyses there was a trend toward higher diagnostic accuracy and better specimen adequacy with EUS-FNB. The lower number of passes needed with EUS-FNB was a common finding in all of them. In contrast with these results, one meta-analysis [6] demonstrated superiority of EUS-FNB over EUS-FNA. Moreover, a very recent network meta-analysis [7] found that EUS-FNA and EUS-FNB were similar (with low confidence in estimates) in terms of diagnostic accuracy, sample adequacy, and histologic core procurement, independently of the gauge of needle used (19, 22 or 25 gauge). However, new meta-analyses using the network methodology are needed to confirm the results. In this issue of Endoscopy, Oppong et al. present a randomized crossover study aimed at comparing fork-tip needle biopsy and FNA when sampling solid pancreatic masses with EUS [1]. In summary, the authors included 108 patients and found that the odds of diagnosing malignancy and the accuracy for a specific diagnosis with EUS-FNB were higher than that of EUS-FNA (3 and 4 times, respectively). Moreover, sampling and pathology viewing times were significantly shorter with EUS-FNB compared with EUS-FNA. Ease-of-diagnosis was also greater with FNB and the cost was comparable between the two types of EUS-guided tissue acquisition. Therefore, the results of this study support the use of EUS-guided fork-tip needle biopsy over EUS-FNA in solid pancreatic masses. A relevant issue in EUS-FNA is the need for on-site evaluation of the sample, as published data demonstrate that it results in significantly fewer repeat EUS-FNA sessions to reach a diagnosis [8]. In contrast, some data suggest that the use of EUS-FNB with acquisition of adequate core tissue may avoid the need for on-site evaluation of the sample [9]. This might represent a substantial improvement in centers where the availability of a pathologist or expert cytotechnician is lacking. In the study by Oppong et al., there was no on-site evaluation of the sample obtained by EUS-FNA. Thus, it might be argued that, had a cytotechnician been available, the results may have been different, at least regarding the sampling and pathologist evaluation times. Finally, although molecular testing may be done from a cellular block, mainly if an extra FNA pass is performed, a histological sample is always better. In the era of personalized medicine, the possibility of obtaining tissue from the tumor will be progressively more necessary to improve patient outcomes. EUS-guided tissue acquisition has become crucial in the diagnosis of solid pancreatic neoplasms because of its ability to perform safe sampling of the pancreas, although it has not impacted medical therapy to date. Hopefully, a deeper knowledge of the molecular pathways for pancreatic cancer development will lead to the improvement of targeted therapies in the near future, extending the role of EUS-guided tissue acquisition from an exclusively diagnostic tool to both diagnostic and therapeutic use. The improvement in the EUS-FNB needles, together with the performance of well-designed comparative studies to optimize needle design for specific lesions, is the next step to an...
- 27 May 2020
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 52 (06) , 427-428
Novel design fine-needle biopsy needles are ready to take over the supremacy of fine-needle aspiration needles for sampling of solid pancreatic masses
Endoscopic ultrasound (EUS)-guided tissue acquisition is a well-established method for pathological diagnosis of solid tumors wherever the needle can reach. However, there is currently conflicting evidence on whether any specific needle or technique is superior to others. The use of EUS-guided fine-needle biopsy (FNB) needles has generated great interest, based on theoretical advantages over EUS fine-needle aspiration (FNA) needles in improving diagnostic accuracy (if we assume that a bigger sample is better, which is not always true), procurement of samples with preserved tissue (as cytology does not inform on the architecture of the lesion), and allowing immunohistochemistry or special stains required for certain diagnoses. “...the results of this study support the use of EUS-FNB with a fork-tip needle over EUS-FNA in solid pancreatic masses.” Attempts to obtain core tissue samples by EUS require cutting mechanisms. The first device was a trucut needle that had a high number of technical failures and was soon taken off the market. The reverse bevel needle was the first core biopsy needle widely used but, after initial promising results, it did not show unequivocal superiority over FNA. Over the past few years, new core biopsy needles have been manufactured with the aim of assessing an adequate tissue sample while avoiding the technical difficulties that usually appear when sampling the head of the pancreas from the duodenum. One such needle is the fork-tip, opposing bevel design, equipped with six cutting surfaces in an asymmetrical design. This is the EUS-FNB needle used in the study performed by Oppong et al. published in the current issue of Endoscopy [1]. The other is the Franseen design needle that has a three-plane symmetrical cutting surface. Both needles have been designed to maximize tissue capture and minimize fragmentation in order to acquire architecturally intact tissue. Many articles with various methodological designs attempting to assess the performance of different needles in solid pancreatic masses have been published in recent years. Technical tips for tissue acquisition and the impact of on-site evaluation of the sample have been repeatedly tested as well. Moreover, several randomized controlled trials (RCTs) have compared EUS-FNA and EUS-FNB in this setting but reached inconsistent results. Five meta-analyses on the subject were also published within the past 4 years. Among the meta-analyses published to date, most of them [2–4] did not find significant differences between the two methods of tissue sampling in terms of diagnostic accuracy, which is in concordance with the most recent update of European guidelines that recommend FNA and FNB equally for routine sampling of solid masses [5]. However, in most of the mentioned meta-analyses there was a trend toward higher diagnostic accuracy and better specimen adequacy with EUS-FNB. The lower number of passes needed with EUS-FNB was a common finding in all of them. In contrast with these results, one meta-analysis [6] demonstrated superiority of EUS-FNB over EUS-FNA. Moreover, a very recent network meta-analysis [7] found that EUS-FNA and EUS-FNB were similar (with low confidence in estimates) in terms of diagnostic accuracy, sample adequacy, and histologic core procurement, independently of the gauge of needle used (19, 22 or 25 gauge). However, new meta-analyses using the network methodology are needed to confirm the results. In this issue of Endoscopy, Oppong et al. present a randomized crossover study aimed at comparing fork-tip needle biopsy and FNA when sampling solid pancreatic masses with EUS [1]. In summary, the authors included 108 patients and found that the odds of diagnosing malignancy and the accuracy for a specific diagnosis with EUS-FNB were higher than that of EUS-FNA (3 and 4 times, respectively). Moreover, sampling and pathology viewing times were significantly shorter with EUS-FNB compared with EUS-FNA. Ease-of-diagnosis was also greater with FNB and the cost was comparable between the two types of EUS-guided tissue acquisition. Therefore, the results of this study support the use of EUS-guided fork-tip needle biopsy over EUS-FNA in solid pancreatic masses. A relevant issue in EUS-FNA is the need for on-site evaluation of the sample, as published data demonstrate that it results in significantly fewer repeat EUS-FNA sessions to reach a diagnosis [8]. In contrast, some data suggest that the use of EUS-FNB with acquisition of adequate core tissue may avoid the need for on-site evaluation of the sample [9]. This might represent a substantial improvement in centers where the availability of a pathologist or expert cytotechnician is lacking. In the study by Oppong et al., there was no on-site evaluation of the sample obtained by EUS-FNA. Thus, it might be argued that, had a cytotechnician been available, the results may have been different, at least regarding the sampling and pathologist evaluation times. Finally, although molecular testing may be done from a cellular block, mainly if an extra FNA pass is performed, a histological sample is always better. In the era of personalized medicine, the possibility of obtaining tissue from the tumor will be progressively more necessary to improve patient outcomes. EUS-guided tissue acquisition has become crucial in the diagnosis of solid pancreatic neoplasms because of its ability to perform safe sampling of the pancreas, although it has not impacted medical therapy to date. Hopefully, a deeper knowledge of the molecular pathways for pancreatic cancer development will lead to the improvement of targeted therapies in the near future, extending the role of EUS-guided tissue acquisition from an exclusively diagnostic tool to both diagnostic and therapeutic use. The improvement in the EUS-FNB needles, together with the performance of well-designed comparative studies to optimize needle design for specific lesions, is the next step to an...
- Open Access
- 23 October 2018
- Published by Elsevier in Annals of Oncology
- Vol. 29 (suppl_8) , viii203
AVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)
Background: Monoclonal antibodies against checkpoint inhibitors (CHKPNT) such as pembrolizumab showed clinical benefit in patients with microsatellite instability (MSI) in mCRC but not in MSS patients. Cancer vaccines with ADC could be a complementary therapeutic approach to CHKPNT. We previously conducted a negative randomized phase II trial in mCRC patients refractory to standard therapy, with ADC compared to the best supportive (Eur J Cancer 64:167-74, 2016). A phase I-II multicentric trial with avelumab (anti-PD-L1) plus ADC vaccine in pre-treated MSS mCRC patients began in April 2018 (NCT03152565).
- 23 October 2018
- Published by Elsevier in Annals of Oncology
- Vol. 29 (suppl_8) , viii203
Open AccessAVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)
Background: Monoclonal antibodies against checkpoint inhibitors (CHKPNT) such as pembrolizumab showed clinical benefit in patients with microsatellite instability (MSI) in mCRC but not in MSS patients. Cancer vaccines with ADC could be a complementary therapeutic approach to CHKPNT. We previously conducted a negative randomized phase II trial in mCRC patients refractory to standard therapy, with ADC compared to the best supportive (Eur J Cancer 64:167-74, 2016). A phase I-II multicentric trial with avelumab (anti-PD-L1) plus ADC vaccine in pre-treated MSS mCRC patients began in April 2018 (NCT03152565).
- 1 October 2017
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 40 (8) , 507-514
Pólipos gástricos: análisis retrospectivo de 41.253 endoscopias digestivas altas
- 1 October 2017
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 40 (8) , 507-514
Pólipos gástricos: análisis retrospectivo de 41.253 endoscopias digestivas altas
- Open Access
- 7 February 2017
- Published by Wiley in Gastroenterology Research and Practice
- Vol. 2017, 1-7
Accuracy of Colon Capsule Endoscopy in Detecting Colorectal Polyps in Individuals with Familial Colorectal Cancer: Could We Avoid Colonoscopies?
Background. Individuals with a family history of colorectal cancer (CRC) have an increased risk of CRC. We evaluated the diagnostic yield of CCE in the detection of lesions and also two different colon preparations. Methods. A prospective multicenter study was designed to assess CCE diagnostic yield in a cohort of asymptomatic individuals with a family history of CRC. CCE and colonoscopy were performed on the same day by 2 endoscopists who were blinded to the results of the other procedure. Results. Fifty-three participants were enrolled. The sensitivity, specificity, PPV, and NPV of CCE for detecting advanced adenomas were 100%, 98%, 67%, and 100%. Sensitivity, specificity, PPV, and NPV of CCE for the diagnosis of individuals with polyps were 87%, 97%, 93%, and 88%, respectively. CCE identify 100% of individuals with significant or advanced lesions. Overall cleanliness was adequate by 60.7% of them. The PEG-ascorbic boost seems to improve colon cleanliness, with similar colonic transit time. Conclusion. CCE is a promising tool, but it has to be considered as an alternative technique in this population in order to reduce the number of colonoscopies performed. More studies are needed to understand appropriate screening follow-up intervals and optimize the bowel preparation regimen.
- 7 February 2017
- Published by Wiley in Gastroenterology Research and Practice
- Vol. 2017, 1-7
Open AccessAccuracy of Colon Capsule Endoscopy in Detecting Colorectal Polyps in Individuals with Familial Colorectal Cancer: Could We Avoid Colonoscopies?
Background. Individuals with a family history of colorectal cancer (CRC) have an increased risk of CRC. We evaluated the diagnostic yield of CCE in the detection of lesions and also two different colon preparations. Methods. A prospective multicenter study was designed to assess CCE diagnostic yield in a cohort of asymptomatic individuals with a family history of CRC. CCE and colonoscopy were performed on the same day by 2 endoscopists who were blinded to the results of the other procedure. Results. Fifty-three participants were enrolled. The sensitivity, specificity, PPV, and NPV of CCE for detecting advanced adenomas were 100%, 98%, 67%, and 100%. Sensitivity, specificity, PPV, and NPV of CCE for the diagnosis of individuals with polyps were 87%, 97%, 93%, and 88%, respectively. CCE identify 100% of individuals with significant or advanced lesions. Overall cleanliness was adequate by 60.7% of them. The PEG-ascorbic boost seems to improve colon cleanliness, with similar colonic transit time. Conclusion. CCE is a promising tool, but it has to be considered as an alternative technique in this population in order to reduce the number of colonoscopies performed. More studies are needed to understand appropriate screening follow-up intervals and optimize the bowel preparation regimen.
- 1 November 2016
- Published by Elsevier in Medicina Clinica
- Vol. 147 (10) , 465.e1-465.e8
Recomendaciones para el diagnóstico, la estadificación y el tratamiento de las lesiones premalignas y el adenocarcinoma de páncreas
- 1 November 2016
- Published by Elsevier in Medicina Clinica
- Vol. 147 (10) , 465.e1-465.e8
Recomendaciones para el diagnóstico, la estadificación y el tratamiento de las lesiones premalignas y el adenocarcinoma de páncreas
- 1 September 2016
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 28 (9) , 1094-1099
Impact of endoscopic ultrasonography (EUS) and EUS-guided fine-needle aspiration on the management of pancreatic cystic lesions
Background and study aims: Endoscopic ultrasonography (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) are well-recognized techniques for the study of pancreatic cystic lesions (PCLs). However, little evidence exists on their impact on clinical care. The aim of this study is to determine how often EUS and EUS-FNA alter the diagnosis and management of patients with PCLs. Patients and methods: Eight physicians expert in pancreatic diseases were asked to report their diagnoses and management recommendations for 49 different PCLs. Clinical information was sequentially disclosed in a stepwise manner – progressively from clinical data plus computed tomography or MRI (level 1), to EUS (level 2) and EUS-FNA results including cytology, carcinoembryonic antigen, and amylase levels (level 3). Results: EUS led to a change in the diagnosis and management in 30% [95% confidence interval (CI): 26–35%] and 19% (95% CI: 16–23%) of cases, respectively, usually to a more intensive approach (14%; 95% CI: 11–18%). EUS-FNA altered the diagnosis and management in an additional 39% (95% CI: 34–44%) and 21% (95% CI: 17–25%) of the evaluations, respectively. EUS-FNA also increased the consensus in the diagnosis among the specialists that ranged from fair with computed tomography/MRI (κ-index=0.32) to substantial with EUS-FNA (κ-index=0.43). Conclusion: EUS and EUS-FNA impact the diagnosis and management of patients with PCLs; therefore, both are necessary in the workup of these patients. EUS-FNA markedly improves the agreement between physicians in terms of diagnosis, but not management. This study highlights the need for more research and standardization in the field.
- 1 September 2016
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 28 (9) , 1094-1099
Impact of endoscopic ultrasonography (EUS) and EUS-guided fine-needle aspiration on the management of pancreatic cystic lesions
Background and study aims: Endoscopic ultrasonography (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) are well-recognized techniques for the study of pancreatic cystic lesions (PCLs). However, little evidence exists on their impact on clinical care. The aim of this study is to determine how often EUS and EUS-FNA alter the diagnosis and management of patients with PCLs. Patients and methods: Eight physicians expert in pancreatic diseases were asked to report their diagnoses and management recommendations for 49 different PCLs. Clinical information was sequentially disclosed in a stepwise manner – progressively from clinical data plus computed tomography or MRI (level 1), to EUS (level 2) and EUS-FNA results including cytology, carcinoembryonic antigen, and amylase levels (level 3). Results: EUS led to a change in the diagnosis and management in 30% [95% confidence interval (CI): 26–35%] and 19% (95% CI: 16–23%) of cases, respectively, usually to a more intensive approach (14%; 95% CI: 11–18%). EUS-FNA altered the diagnosis and management in an additional 39% (95% CI: 34–44%) and 21% (95% CI: 17–25%) of the evaluations, respectively. EUS-FNA also increased the consensus in the diagnosis among the specialists that ranged from fair with computed tomography/MRI (κ-index=0.32) to substantial with EUS-FNA (κ-index=0.43). Conclusion: EUS and EUS-FNA impact the diagnosis and management of patients with PCLs; therefore, both are necessary in the workup of these patients. EUS-FNA markedly improves the agreement between physicians in terms of diagnosis, but not management. This study highlights the need for more research and standardization in the field.
- Open Access
- 20 June 2016
- Published by Springer Nature in Surgical Endoscopy
- Vol. 31 (2) , 723-733
Endoscopic tattooing of early colon carcinoma enhances detection of lymph nodes most prone to harbor tumor burden
Background Colorectal cancer (CRC) screening programs result in the detection of early-stage asymptomatic carcinomas suitable to be surgically cured. Lymph nodes (LN) from early CRC are usually small and may be difficult to collect. Still, at least 12 LNs should be analyzed from colectomies, to ensure a reliable pN0 stage. Presurgical endoscopic tattooing improves LN procurement. In addition, molecular detection of occult LN tumor burden in histologically pN0 CRC patients is associated with a decreased survival rate. We aimed to study the impact of presurgical endoscopic tattooing on the molecular detection of LN tumor burden in early colon neoplasms. Methods A prospective cohort study from a CRC screening-based population was performed at a tertiary academic hospital. LNs from colectomies with and without preoperative endoscopic tattooing were assessed by two methods, hematoxylin and eosin (HE), and RT-LAMP, to detect tumor cytokeratin 19 (CK19) mRNA. We compared the amount of tumor burden and LN yields from tattooed and non-tattooed specimens. Results HE and RT-LAMP analyses of 936 LNs were performed from 71 colectomies containing early carcinomas and endoscopically unresectable adenomas (8 pT0, 17 pTis, 27 pT1, 19 pT2); 47 out of 71 (66.2 %) were tattooed. Molecular positivity correlated with the presence of tattoo in LN [p < 0.001; OR 3.1 (95 % CI 1.7–5.5)]. A significantly higher number of LNs were obtained in tattooed specimens (median 17 LN vs. 14.5 LN; p = 0.019). Conclusions Endoscopic tattooing enables the analysis of those LNs most prone to harbor tumor cells and improves the number of LN harvested.
- 20 June 2016
- Published by Springer Nature in Surgical Endoscopy
- Vol. 31 (2) , 723-733
Open AccessEndoscopic tattooing of early colon carcinoma enhances detection of lymph nodes most prone to harbor tumor burden
Background Colorectal cancer (CRC) screening programs result in the detection of early-stage asymptomatic carcinomas suitable to be surgically cured. Lymph nodes (LN) from early CRC are usually small and may be difficult to collect. Still, at least 12 LNs should be analyzed from colectomies, to ensure a reliable pN0 stage. Presurgical endoscopic tattooing improves LN procurement. In addition, molecular detection of occult LN tumor burden in histologically pN0 CRC patients is associated with a decreased survival rate. We aimed to study the impact of presurgical endoscopic tattooing on the molecular detection of LN tumor burden in early colon neoplasms. Methods A prospective cohort study from a CRC screening-based population was performed at a tertiary academic hospital. LNs from colectomies with and without preoperative endoscopic tattooing were assessed by two methods, hematoxylin and eosin (HE), and RT-LAMP, to detect tumor cytokeratin 19 (CK19) mRNA. We compared the amount of tumor burden and LN yields from tattooed and non-tattooed specimens. Results HE and RT-LAMP analyses of 936 LNs were performed from 71 colectomies containing early carcinomas and endoscopically unresectable adenomas (8 pT0, 17 pTis, 27 pT1, 19 pT2); 47 out of 71 (66.2 %) were tattooed. Molecular positivity correlated with the presence of tattoo in LN [p < 0.001; OR 3.1 (95 % CI 1.7–5.5)]. A significantly higher number of LNs were obtained in tattooed specimens (median 17 LN vs. 14.5 LN; p = 0.019). Conclusions Endoscopic tattooing enables the analysis of those LNs most prone to harbor tumor cells and improves the number of LN harvested.
- 1 April 2016
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 83 (4) , 780-784
Adverse events of EUS-guided FNA of pancreatic cystic and solid lesions by using the lexicon proposed in an ASGE workshop: a prospective and comparative study
- 1 April 2016
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 83 (4) , 780-784
Adverse events of EUS-guided FNA of pancreatic cystic and solid lesions by using the lexicon proposed in an ASGE workshop: a prospective and comparative study